U.S. market Closed. Opens in 17 hours 16 minutes

RXRX | Recursion Pharmaceuticals, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
Revenue44.58M39.68M10.00M3.41M1.71M
Cost of Revenue51.09M48.27M9.10M63.32M45.81M
Gross Profit-6.51M-8.59M896.00K-59.91M-44.10M
Operating Expenses343.55M237.13M192.78M88.03M64.15M
Selling, General & Admin110.82M81.60M57.68M25.26M18.95M
Research & Development232.73M155.70M135.27M63.32M45.81M
Other Operating Expenses-1.09M-162.00K-178.00K-549.00K-608.00K
Operating Income-350.06M-245.73M-182.78M-84.61M-62.44M
Other Expenses / Income17.93M6.25M-3.70M-2.39M562.00K
Before Tax Income-332.13M-239.48M-186.48M-87.01M-61.88M
Income Tax Expenses-4.06M-55.00K-8.40M876.00K646.00K
Net Income-328.07M-239.42M-178.07M-87.88M-62.52M
Interest Expenses97.00K55.00K2.95M1.36M635.00K
Basic Shares Outstanding207.85M175.54M170.27M165.79M165.79M
Diluted Shares Outstanding207.85M175.54M170.27M165.79M165.79M
EBITDA-317.60M-245.73M-182.78M-80.32M-58.20M
EBITDA Margin-712.50%-619.26%-1,827.75%-2,353.38%-3,401.52%
EBIT-332.03M-239.42M-183.53M-85.65M-61.24M
EBIT Margin-744.88%-603.36%-1,835.27%-2,509.41%-3,579.43%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙